It is tempting to open a page like this with a superlative and move on. We will not, because a superlative you cannot check is worth nothing, and because the people reading this are precisely the people who should not accept claims they cannot verify. So here is the honest version: quality in cryopreservation is not a vibe and it is not a brochure adjective. It is a measurable property of a single biological structure, the brain, and it is decided almost entirely by how much damage that structure takes in the minutes and hours after legal death.
If you understand that one sentence, you can evaluate any provider in the world, including us. The thing that decides quality is ischemia, the oxygen starvation that begins the instant the heart stops, and the speed and evenness with which cryoprotectant reaches the tissue. Everything below is just the engineering of getting those two numbers as good as they can be. Judge us against it.
The whole game is minimizing ischemia
The moment a heart stops, a clock starts, and it does not stop ticking for anyone. Without oxygen the brain begins to degrade, and every minute of delay costs structural fidelity that no later step can recover. This is the race against cellular decay, and it is the master variable under which every other quality claim sits.
So when someone asks how good a preservation was, the rigorous answer is not a marketing word. It is a set of numbers: how long was the patient ischemic, at what temperatures, how fast were they cooled, how evenly did the protectant perfuse. A provider that is genuinely good at preservation is a provider that is good at making those numbers small, and that is willing to write them down afterward. Hold that frame, and the differentiators below stop being boasts and become claims you can test.
Standby is where the minutes are won or lost
Most of the irreversible damage in cryonics happens not in the operating room but in the gap before anyone qualified arrives. If a team reaches the patient hours after death, no amount of downstream excellence can undo that head start the ischemia got.
This is why we run a professional 24/7 standby and stabilization capability with teams based in Berlin and Amsterdam rather than a single distant facility. The point of two European bases is geometric: more bases, closer to more members, means shorter response times, means less ischemia, means better odds for the only structure that matters. When a member is near the end, the team can be positioned in advance, so that cooling and circulatory support begin within minutes of legal death rather than after a long drive. We describe the full sequence in what actually happens the moment you need us.
Field cryoprotection, not transport-then-perfuse
Here is a differentiator that is concrete enough to verify. Tomorrow.bio performs professional whole-body field cryoprotection on-site in Europe, near the place of death, rather than shipping a cold-but-unprotected body across a continent and perfusing it on arrival.
The reason this matters comes straight from the ischemia frame. Cooling buys you time, but cooling alone does not replace the body's water with protectant, and until that replacement happens the tissue is still vulnerable to ice. The sooner the cryoprotectant goes in, and the more evenly it perfuses, the closer you get to a clean vitrification and the further you stay from damaging crystal formation. Doing that step in the field, rather than after hours or days of transport, is one of the largest levers on final quality that any provider has. It is also, candidly, the harder and more expensive way to do it, which is part of why it is rare.
State-of-the-art protectant and stable Swiss storage
Once the patient is perfused, the question becomes whether the glass holds for the decades or centuries it may need to. We use current-generation cryoprotectant agents designed to vitrify reliably while keeping toxicity as low as the chemistry currently allows, and we cool through the glass transition in a controlled way to limit fracturing.
Long-term storage then happens not inside a startup but inside the non-profit European Biostasis Foundation facility in Switzerland, the Swiss facility that convinced the skeptics. Separating the company that signs you up from the foundation that holds you is deliberate. It means the institution responsible for keeping the nitrogen topped up for a century is structured to outlive the commercial entity, which is exactly the kind of boring durability you want underneath a 200,000 EUR bet. Why a European base changes the whole logistics picture is its own argument, laid out in why a European provider changes everything.
We try to measure quality, not just assert it
The most honest thing a provider can do is refuse to grade its own homework by feel. For decades, preservation quality across the field was described qualitatively, which is a polite way of saying anecdotally. We would rather move it onto numbers.
That means per-case quality-check procedures: documenting the timeline, recording the cooling curve, assessing how evenly perfusion reached the tissue, and quantifying ischemic exposure with a standardized metric (see the S-MIX approach). Measurement does two things. It lets us compare cases and improve protocols by evidence rather than story, and it produces a real record that travels with the patient into the future. A provider willing to measure quality is implicitly admitting that quality varies between cases, which it does, and that honesty is itself a quality signal.
Quality in cryopreservation is not a slogan. It is a small set of numbers about ischemia and perfusion, and the only providers worth trusting are the ones who work to make those numbers good and then write them down.
So we will not tell you we are the best in the world and ask you to take it on faith. We will tell you what decides quality, show you the specific things we do to win on it, and commit to measuring the result. If a competitor reaches members faster, perfuses more evenly, and stores more stably, that competitor is producing better preservations, and we should both want that bar to rise. The honest claim is narrower and sturdier than a superlative: we are built, end to end, around minimizing ischemia, and that is the thing that matters.